Budesonide Inhaler Market To Surpass US$ 8.24 Billion By 2026 - Coherent Market Insights


Posted January 15, 2021 by SANJAYCMI

“Coherent Market Insights “BUDESONIDE INHALER MARKET – GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027″
 
Global Budesonide Inhaler Market, by Product Type (Inhalants and Nebulizer), by Dosage (Aerosols, Dry Powder, Suspension, and Sprays), by Strength (0.25mg, 0.5mg, and 1.0mg), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 4.85 billion in 2017, and is projected to exhibit a CAGR of 5.8% over the forecast period (2018 - 2026).

Key players in the market are focused on developing generics version of budesonide inhaler in affordable prices and in various forms such as dry powder, aerosols, suspensions or spray for asthma patients. Increasing number of regulatory approvals for generic versions of budesonide inhaler is a major factor driving growth of the budesonide inhaler market. For instance, in 2018, Lupin received approval for its budesonide inhalation suspension 0.5/2ml single dose ampules from the U.S.FDA to market generic versions AstraZeneca’s Pulmicort Respules. It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2551

Moreover, key manufacturers are also focused on developing new combinations of budesonide inhaler with other drugs to enhance their market share. Budesonide can be made in combination with formoterol. In September 2016, Orion Corporation announced that it has entered into a collaboration agreement with Menarini Group for the co-marketing of budesonide-formoterol Easyhaler combination product in Germany, Italy, Spain, and Portugal. Budesonide-formoterol Easyhaler is an inhaled combination product indicated for asthma and chronic obstructive pulmonary disease (COPD). In this formulation, budesonide acts as an anti-inflammatory agent and formoterol acts as a long-acting bronchodilator. The product is available under the brand name Bufomix Easyhaler in most of the European countries.

Browse 21 Market Data Tables and 19 Figures spread through 149 Pages and in-depth TOC on "Global Budesonide Inhaler Market, by Product Type (Inhalants and Nebulizer), by Dosage (Aerosols, Dry Powder, Suspension, and Sprays), by Strength (0.25mg, 0.5mg, and 1.0mg), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" To know the latest trends and insights related to budesonide inhaler market.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/budesonide-inhaler-market-2551

Key Takeaways of the Budesonide Inhaler Market:

The global budesonide inhaler market is expected to witness a CAGR of 5.8% during the forecast period (2018–2026), owing to increasing number of regulatory approvals for generic versions of budesonide inhaler

Among product type, the inhalant segment is expected to hold major revenue share in the market over the forecast period.

Key players in the market are focused on developing generic versions of budesonide inhaler for asthma and COPD, which is expected to drive growth of the inhalant segment in the market. For instance, in 2017, Cipla Ltd. received final approval for Budesonide Inhalation Suspension, from the U.S. FDA to market a generic version of AstraZeneca's Pulmicort Respules.

Major players operating in the global budesonide inhaler market include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2551

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags Budesonide Inhaler Market Research , Budesonide Inhaler , Budesonide Inhaler Market Growth
Last Updated January 15, 2021